alglucosidase alfa

al·glu·co·si·dase al·fa (al-gloo-koґsĭ-dās alґfə) a recombinant form of the enzyme α-1,4-glucosidase, used in treatment of glycogen storage disease, type II; administered by intravenous infusion.

Medical dictionary. 2011.

Look at other dictionaries:

  • Alglucosidase alfa — Systematic (IUPAC) name Human glucosidase, prepro α [199 arginine,223 histidine] [1] Clinical data AHFS/Drugs.com …   Wikipedia

  • АТХ код A16 — АТХ A «Препараты, влияющие на пищеварительный тракт и обмен веществ» АТХ код A01 Стоматологические препараты АТХ код A02 Препараты для лечения заболеваний, связанных с нарушением кислотности АТХ код A03 Препараты для лечения функциональных… …   Википедия

  • Morbus Pompe — Klassifikation nach ICD 10 E74.0 Glykogenspeicherkrankheit …   Deutsch Wikipedia

  • Enfermedad de Pompe — Clasificación y recursos externos CIE 10 E …   Wikipedia Español

  • Glycogen storage disease type II — Infobox Disease Name = Glycogen storage disease type II Caption = DiseasesDB = 5296 ICD10 = ICD10|E|74|0|e|70 ICD9 = ICD9|271.0 ICDO = OMIM = 232300 MedlinePlus = eMedicineSubj = med eMedicineTopic = 908 eMedicine mult = eMedicine2|ped|1866 |… …   Wikipedia

  • Maladie de Pompe — Référence MIM 232300 Transmission Récessive Chromosome 17 q25.2 q25.3 Gène GAA Empreinte parentale Non …   Wikipédia en Français

  • Carnitine — Systematic (IUPAC) name 3 hydroxy 4 (trimethylazaniumyl)butanoate Clinical data AHFS/Drugs.com …   Wikipedia

  • Tetrahydrobiopterin — Systematic (IUPAC) name (6R) 2 Amino 6 [(1R,2S) 1,2 dihydroxypropyl] 5,6,7,8 tetrahydropteridin 4(1H) one Clinical data …   Wikipedia

  • Alglucerase — Systematic (IUPAC) name Human beta glucocerebrosidase Clinical data AHFS/Drugs.com monograph MedlinePlus …   Wikipedia

  • Imiglucerase — Systematic (IUPAC) name Human Beta glucocerebrosidase Clinical data AHFS/Drugs.com monograph MedlinePlus …   Wikipedia

Share the article and excerpts

Direct link
Do a right-click on the link above
and select “Copy Link”

We are using cookies for the best presentation of our site. Continuing to use this site, you agree with this.